Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Outset Medical, Inc.NASDAQ: OM
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 43.4%
Gross margin was 43.4% in Q1 FY2026, up 6.2 pp from a year earlier. On a trailing-twelve-month basis it was 40.6%, up 4.7 pp year over year. Over 3 fiscal years it widened by 23.7 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 39.1%
- Year-over-year change
- +5.2pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.1% | +5.2pp |
| FY2024 | 2024-12-31 | 33.9% | +11.7pp |
| FY2023 | 2023-12-31 | 22.2% | +6.8pp |
| FY2022 | 2022-12-31 | 15.5% | +8.0pp |
| FY2021 | 2021-12-31 | 7.4% | — |
Gross Margin vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 gross margin of 40.6% is the 8th highest of the 10 companies compared; the peer median is 57.3%.
- Its year-over-year change of +4.7 pp is the 2nd highest of 9, against a peer median of -1.2 pp.
- Over three fiscal years its change of +23.7 pp compares with a peer median of +3.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 144.9% | — | — | |
| LTM Mar 2026 | 94.2% | +127.8 pp | +50.5 pp | |
| LTM Mar 2026 | 75.7% | -0.9 pp | +3.0 pp | |
| LTM Mar 2026 | 75.5% | +0.4 pp | — | |
| LTM Mar 2026 | 57.3% | -1.4 pp | -3.5 pp | |
| LTM Mar 2026 | 48.7% | +2.6 pp | +6.9 pp | |
| LTM Mar 2026 | 44.1% | -15.0 pp | +3.7 pp | |
| LTM Mar 2026 | 40.6% | +4.7 pp | +23.7 pp | |
| LTM Dec 2025 | -98.2% | -3.3 pp | -18.0 pp | |
| LTM Mar 2026 | -489.8% | -407.5 pp | -290.8 pp | |
| Peer median (excluding OM) | 57.3% | -1.2 pp | +3.0 pp | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 102.6M | 115.38M | 130.38M | 113.69M | 119.48M |
| Cost of Revenue | 94.99M | 97.54M | 101.38M | 75.13M | 72.72M |
| Gross Profit | 7.61M | 17.83M | 29M | 38.56M | 46.75M |
| Gross Margin | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Research & Development | 36.74M | 48.86M | 57.31M | 38.4M | 21.24M |
| Selling, General & Admin | 101.39M | 130M | 141.46M | 113.54M | 92.23M |
| Operating Expenses | 138.13M | 178.85M | 198.77M | 151.94M | 113.46M |
| Depreciation & Amortization | 5.16M | 6.28M | 5.81M | 5.73M | 4.34M |
| EBITDA | (124.86M) | (152.81M) | (153.79M) | (97.89M) | (62.37M) |
| EBITDA Margin | -121.7% | -132.4% | -118.0% | -86.1% | -52.2% |
| Operating Income | (130.52M) | (161.02M) | (169.77M) | (113.38M) | (66.71M) |
| Operating Margin | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Interest Income | 498K | 3.29M | 10.17M | 9.76M | 7.41M |
| Interest Expense | 1.72M | 3.57M | 12.68M | 23.87M | 13.95M |
| Other Income / Expenses | (1.22M) | (1.64M) | (2.5M) | (14.11M) | (14.22M) |
| Income Before Tax | (131.74M) | (162.66M) | (172.27M) | (127.49M) | (80.94M) |
| Pre-Tax Margin | -128.4% | -141.0% | -132.1% | -112.1% | -67.7% |
| Income Tax Expense | 199K | 295K | 523K | 491K | 718K |
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Net Margin | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| EPS (Basic) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| EPS (Diluted) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| Weighted Avg Shares | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
| Weighted Avg Shares (Diluted) | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.